vinculin Inhibitors

Common vinculin Inhibitors include, but are not limited to Withaferin A CAS 5119-48-2, Cytochalasin D CAS 22144-77-0, Y-27632 dihydrochloride monohydrate CAS 129830-38-2, (S)-(-)-Blebbistatin CAS 856925-71-8 and NSC 23766 CAS 733767-34-5.

Vinculin, a cytoskeletal protein predominantly found in focal adhesions, plays a critical role in cell adhesion, migration, and mechanotransduction. Functioning as a molecular linker between the actin cytoskeleton and the extracellular matrix, vinculin contributes to the stability and dynamics of cell-cell and cell-substrate interactions. Through its interactions with various signaling molecules and structural proteins, vinculin regulates cellular processes such as cell spreading, migration, and tissue organization, thereby influencing diverse physiological phenomena including embryonic development, wound healing, and tissue homeostasis.

Inhibition of vinculin activity disrupts its normal functions, leading to aberrations in cell adhesion dynamics and cellular signaling pathways. Mechanistically, inhibition of vinculin can occur through various pathways, including interference with its binding to other proteins or with its conformational changes. Disruption of the vinculin-actin interaction or prevention of its recruitment to focal adhesions impedes the assembly of focal adhesion complexes and compromises cellular adhesion and migration processes. Additionally, inhibition of upstream regulators or downstream effectors of vinculin signaling pathways can indirectly affect vinculin function. Overall, inhibition of vinculin activity can result in impaired cell adhesion, altered cytoskeletal organization, and perturbed cellular signaling, contributing to pathological conditions such as cancer metastasis, tissue fibrosis, and cardiovascular diseases.